OncoGenex announces public offering of common stock

NewsGuard 100/100 Score
Oct 19 2010

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it is commencing a public offering of its common stock and warrants to purchase shares of its common stock.  OncoGenex intends to use the net proceeds from the offering primarily to advance its product pipeline, including its lead program, custirsen, and OGX-427, which is currently in clinical development as a treatment for prostate cancer and bladder cancer, as well as for general corporate purposes. 

Stifel Nicolaus Weisel is acting as sole book-running manager and Needham & Company, LLC, Rodman & Renshaw, LLC and Wedbush PacGrow Life Sciences are acting as co-managers.

Source:

OncoGenex Pharmaceuticals, Inc.

Posted in:

Tags: , , , , , , , ,

Comments (0)

Suggested Reading

Cancer history raises cardiovascular disease risk in hypertensive patients
Gut microbiome study challenges established cancer biomarkers, identifies new bacterial links to colorectal cancer
Aspirin's immune-boosting effects in colorectal cancer revealed
New sustainable diagnostic approach offers precision cancer testing with minimal environmental impact
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer
Loneliness increases mortality risk in cancer survivors, study finds
How body shape influences colorectal cancer risk
Breast cancer survivors at higher risk of developing second cancers

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study finds major gaps in cancer screening use in Federally Qualified Health Centers